Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01186978 · ClinicalTrials.gov registry record · NA
Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
A NA study of Diffuse Large B Cell Lymphoma, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
- 3
- Study locations
NCT01186978 is a NA study of Diffuse Large B Cell Lymphoma that has completed, run by Duke University. The registered enrollment target is 63 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (71% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT01186978, a NA study of Diffuse Large B Cell Lymphoma, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will evaluate whether a reduction in the radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity. Hypothesis- The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET scan following rituximab-containing chemotherapy.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
Study Locations (3)
North Carolina
- Durham Regional Hospital - Durham
- Duke University Medical Center - Durham
- Duke Raleigh Hospital - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2010-09-20 |
| Est. Completion | 2019-06-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01186978
The ClinicalTrials.gov registry entry for NCT01186978 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (71% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT01186978 reports 3 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01186978 about?
NCT01186978 is a clinical study titled "Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma". This study will evaluate whether a reduction in the radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity. Hypothesis- The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rat...
What is the current status of trial NCT01186978?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2010-09-20. Estimated completion is 2019-06-04.
What conditions does trial NCT01186978 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT01186978?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01186978?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01186978 being conducted?
This trial has 3 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
RECRUITING · NA
-
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
RECRUITING · NA
-
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
ACTIVE NOT RECRUITING · NA
-
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
ACTIVE NOT RECRUITING · NA
-
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · NA
-
Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.